Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K, Mora AR, van Schaik RHN, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin O, von Moos R, Joerger M, Levesque MP, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex SL, Mathijssen R, Metaxas Y. de Joode K, et al. Among authors: metaxas y. J Immunother. 2024 Jun 1;47(5):190-194. doi: 10.1097/CJI.0000000000000506. Epub 2024 Feb 6. J Immunother. 2024. PMID: 38318726
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.
Zarkavelis G, Amylidi AL, Verbaanderd C, Cherny NI, Metaxas Y, de Vries EGE, Zygoura P, Amaral T, Jordan K, Strijbos M, Dafni U, Latino N, Galotti M, Lordick F, Giuliani R, Pignatti F, Pentheroudakis G. Zarkavelis G, et al. Among authors: metaxas y. ESMO Open. 2023 Feb;8(1):100604. doi: 10.1016/j.esmoop.2022.100604. Epub 2022 Nov 14. ESMO Open. 2023. PMID: 36870739 Free PMC article. Review.
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, Stathis A, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Joerger M, et al. Among authors: metaxas y. Cancers (Basel). 2022 Apr 27;14(9):2191. doi: 10.3390/cancers14092191. Cancers (Basel). 2022. PMID: 35565320 Free PMC article.
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali P, Ceresoli GL, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y. Mark M, et al. Among authors: metaxas y. ESMO Open. 2022 Jun;7(3):100446. doi: 10.1016/j.esmoop.2022.100446. Epub 2022 Apr 12. ESMO Open. 2022. PMID: 35427834 Free PMC article.
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Froesch P, Mark M, Rothschild SI, Li Q, Godar G, Rusterholz C, Oppliger Leibundgut E, Schmid S, Colombo I, Metaxas Y, König D, Sessa C, Gautschi O, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Froesch P, et al. Among authors: metaxas y. Lung Cancer. 2021 Jun;156:91-99. doi: 10.1016/j.lungcan.2021.04.002. Epub 2021 Apr 25. Lung Cancer. 2021. PMID: 33933896 Clinical Trial.
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Among authors: metaxas y. Cancer Immunol Immunother. 2021 May;70(5):1255-1262. doi: 10.1007/s00262-020-02757-8. Epub 2020 Nov 1. Cancer Immunol Immunother. 2021. PMID: 33130956 Free PMC article. Clinical Trial.
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Metaxas Y, et al. Ann Oncol. 2020 Apr;31(4):495-500. doi: 10.1016/j.annonc.2019.12.009. Epub 2020 Jan 16. Ann Oncol. 2020. PMID: 32085891 Free article. Clinical Trial.
20 results